Literature DB >> 29857275

Discovery of potent and novel smoothened antagonists via structure-based virtual screening and biological assays.

Wenfeng Lu1, Dihua Zhang1, Haikuo Ma2, Sheng Tian3, Jiyue Zheng1, Qin Wang4, Lusong Luo4, Xiaohu Zhang5.   

Abstract

The Hedgehog (Hh) signaling pathway plays a critical role in controlling patterning, growth and cell migration during embryonic development. Aberrant activation of Hh signaling has been linked to tumorigenesis in various cancers, such as basal cell carcinoma (BCC) and medulloblastoma. As a key member of the Hh pathway, the Smoothened (Smo) receptor, a member of the G protein-coupled receptor (GPCR) family, has emerged as an attractive therapeutic target for the treatment and prevention of human cancers. The recent determination of several crystal structures of Smo in complex with different antagonists offers the possibility to perform structure-based virtual screening for discovering potent Smo antagonists with distinct chemical scaffolds. In this study, based on the two Smo crystal complexes with the best capacity to distinguish the known Smo antagonists from decoys, the molecular docking-based virtual screening was conducted to identify promising Smo antagonists from ChemDiv library. A total of 21 structurally novel and diverse compounds were selected for experimental testing, and six of them exhibited significant inhibitory activity against the Hh pathway activation (IC50 < 10 μM) in a GRE (Gli-responsive element) reporter gene assay. Specifically, the most potent compound (compound 20: 47 nM) showed comparable Hh signaling inhibition to vismodegib (46 nM). Compound 20 was further confirmed to be a potent Smo antagonist in a fluorescence based competitive binding assay. Optimization using substructure searching method led to the discovery of 12 analogues of compound 20 with decent Hh pathway inhibition activity, including four compounds with IC50 lower than 1 μM. The important residues uncovered by binding free energy calculation (MM/GBSA) and binding free energy decomposition were highlighted and discussed. These findings suggest that the novel scaffold afforded by compound 20 can be used as a good starting point for further modification/optimization and the clarified interaction patterns may also guide us to find more potent Smo antagonists.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Antagonist; Molecular docking; Smoothened receptor; Virtual screening

Mesh:

Substances:

Year:  2018        PMID: 29857275     DOI: 10.1016/j.ejmech.2018.05.035

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  4 in total

1.  Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis.

Authors:  Jue Hou; Jie Ju; Zili Zhang; Cong Zhao; Zhanhui Li; Jiyue Zheng; Tian Sheng; Hongjian Zhang; Linkun Hu; Xiaoliang Yu; Wei Zhang; Yangxin Li; Meng Wu; Haikuo Ma; Xiaohu Zhang; Sudan He
Journal:  Cell Death Dis       Date:  2019-06-24       Impact factor: 8.469

2.  Structure-Activity Relationship Studies of Hydantoin-Cored Ligands for Smoothened Receptor.

Authors:  Yang Liu; Fang Zhou; Kang Ding; Dongxiang Xue; Zhihao Zhu; Cuixia Li; Fei Li; Yueming Xu; Fei Xu; Zhiping Le; Suwen Zhao; Houchao Tao
Journal:  ChemistryOpen       Date:  2021-10       Impact factor: 2.630

3.  Discovery of Novel Inhibitor for WNT/β-Catenin Pathway by Tankyrase 1/2 Structure-Based Virtual Screening.

Authors:  Bo Li; Jinxia Liang; Feng Lu; Guandi Zeng; Jindao Zhang; Yinxing Ma; Peng Liu; Qin Wang; Qian Zhou; Liang Chen
Journal:  Molecules       Date:  2020-04-06       Impact factor: 4.411

Review 4.  The Role of Smoothened in Cancer.

Authors:  Kuo-Shyang Jeng; I-Shyan Sheen; Chuen-Miin Leu; Ping-Hui Tseng; Chiung-Fang Chang
Journal:  Int J Mol Sci       Date:  2020-09-18       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.